Historical performance in the Health sector.
Source: Acquire.fyi, Jan 1, 2025 - Jul 13, 2026.
Most active categories within the Health sector.
Source: Acquire.fyi, Jan 1, 2026 - Jul 13, 2026.
Largest mergers and acquisitions by disclosed deal value.
| Acquirer | Target | Type | Value | Headline |
|---|---|---|---|---|
| Abbott Laboratories | Exact Sciences | Acquisition | $21.3B | Abbott Laboratories acquires Exact Sciences in $21,267.5M deal |
| Investor Group | Hologic | Acquisition | $18.4B | Investor Group acquires Hologic in $18,446.7M deal |
| Blackstone and TPG | Hologic, Inc. | Acquisition | $18.3B | Blackstone and TPG to acquire Hologic, Inc. in $18,300.0M cash and contingent value right deal |
| Boston Scientific | Penumbra | Acquisition | $14.2B | Boston Scientific to acquire Penumbra in $14,235.4M deal |
| Sun Pharmaceutical | Organon & Co. | Acquisition | $11.8B | Sun Pharma buys Organon for $11.75 billion |
| Sun Pharmaceutical Industies | Organon & Co | Acquisition | $11.7B | Sun Pharmaceutical Industies to acquire Organon & Co in $11,698.4M deal |
| Danaher | Masimo | Acquisition | $10B | Danaher to acquire Masimo in $10,026.2M deal |
| Danaher Corporation | Masimo Corporation | Acquisition | $9.9B | Danaher Corporation to acquire Masimo Corporation in $9,900.0M cash deal |
| Gilead Sciences | Arcellx | Acquisition | $7.6B | Gilead Sciences acquires Arcellx in $7,589.0M deal |
| Cencora | Covetrus | Merger | $3.5B | Cencora to merge with Covetrus in $3,500.0M cash, preferred equity, and common equity deal |
Page 1 of latest articles and deal coverage.
The acquisition gives IKS an installed hospital software base and a stronger path to bundle AI, revenue cycle, and workflow tools into cash-strapped community providers.
The deal gives Novartis a differentiated antibody drug conjugate engine as large pharma races to secure better-tolerated oncology assets before clinical validation drives prices higher.
The long-term care pharmacy operator is adding a Shenandoah Valley foothold as scale, reimbursement pressure, and local relationships reshape the sector.
The purchase converts a decades-old lease into owned infrastructure, giving NHC tighter control over margins, capital planning, and regional post-acute networks.
The deal adds 3,633 skilled nursing beds and pushes PACS deeper into a fragmented post-acute market where scale, reimbursement discipline, and local operating control increasingly determine returns.
The deal adds a 1,200-person platform business that gives Accenture tighter access to regulated hospital workflows, patient data infrastructure and public sector healthcare spending in Italy.
The TARGAN deal gives Merck tighter control over hatchery workflows where vaccine delivery, labor efficiency, and animal welfare increasingly converge.
The deal adds HEDIS reporting and chart abstraction software as health plans face tighter quality economics and heavier regulatory scrutiny.
The deal extends Vizient’s push beyond traditional supply chain contracting into a fast-growing cost category where hospitals have struggled to control vendor sprawl and pricing.
The $1.2 billion deal shifts Novanta further into recurring medical revenue and tests how much buyers will pay for OEM-facing surgical assets with regulatory and manufacturing depth.
The deal converts a decades-long operating relationship into owned real estate and gives NHC tighter control over cash flow in a reimbursement-driven market.
The deal gives Hims & Hers a larger operating base in regulated overseas markets as it pushes to turn telehealth scale into durable consumer health economics.
The deal gives the telehealth group a local operating base in a tightly regulated market where obesity care demand is rising faster than traditional access.
The asset deal gives Innovaccer billing operations depth in ambulatory care as providers hunt for margin relief and AI vendors race to own the administrative stack.
The buyout removes a public market overhang from a scaled home health and hospice operator as private capital pushes deeper into care delivered at home.
The deal gives IKS Health proprietary medical knowledge graphs and reasoning tools as healthcare AI vendors race to make models cheaper, more auditable, and harder to displace.
The buyout gives Knox Lane a healthcare staffing and labor software platform at a moment when hospitals are still trying to control workforce costs after the pandemic hiring shock.
The all-cash deal gives Sun Pharma scale in women’s health, biosimilars and branded medicines while pushing the Indian drugmaker deeper into global markets and heavier leverage.
The cash deal pairs IKS Health’s AI-led care enablement platform with TruBridge’s rural hospital software base, betting that scale and tighter workflows can help strained providers defend margins and keep care local.
The acquisition gives ModMed a proactive patient engagement layer that can reactivate patients and fill schedules automatically across its specialty practice network.